ETP-ALL has a lower frequency of NOTCH1 mutations and homozygous cyclin-dependent kinase inhibitor 2A/2B (CDKN2A/CDKN2B) deletions. The gene discussed is CDKN2A; the disease is acute lymphoblastic leukemia.